Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS

Show Description +

In this video, Charles C. Wykoff, MD, PhD, FACS, shares highlights from his ASRS talk on intravitreal aflibercept (Eylea, Regeneron) for the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.

Posted: 7/20/2018

Keywords:

Diabetic Retinopathy

•

Eylea

•

Intravitreal Injection

•

Regeneron Pharmaceuticals

Up Next

Name: Key Points From the Phase 3 PANORAMA Study
Uploaded: 2018-07-20T21:21:00+00:00
Description: In this video, Charles C. Wykoff, MD, PhD, FACS, shares highlights from his ASRS talk on intravitreal aflibercept (Eylea, Regeneron) for the treatment of patients with moderately severe to severe nonproliferative diabetic retinopathy.

The Future of Global Trends in Retina

Ehab N. El Rayes, MD, PhD, Paul Hahn, MD, PhD

How Has the Value of Retinal Procedures Changed?

Pravin U. Dugel, MD, Timothy G. Murray, MD, MBA

Here's the DRIL

Amy Babiuch, MD

Complications Associated With Nd:YAG Laser Vitreolysis

Paul Hahn, MD, PhD

Early Signs of Efficacy for a Bioengineered RPE Patch

Amir H. Kashani, MD, PhD

Women in Retina

Anne E. Fung, MD, Jennifer I. Lim, MD, Nancy M. Holekamp, MD

Surgical Repair of Macular Holes

Raymond Iezzi, MD, MS

Head-to-Head Comparison for nAMD Treatment

Arshad M. Khanani, MD

Highlights From the Phase 3 Chroma and Spectri Trials

Carl D. Regillo, MD, FACS

Phase 1b-2 Results of a Novel Targeted Therapy for Treatment of Choroidal Melanoma

Amy C. Schefler, MD, FACS

The ASRS Takes Vancouver

Timothy G. Murray, MD, MBA

A Role for Biosimilars in Retina?

Alay S. Banker, MD, Charles C. Wykoff, MD, PhD, FACS

Visual Acuity Outcomes in Patients With Persistent DME Receiving Adjunctive Therapy

Raj K. Maturi, MD

A Look at Treatment Burden Associated With Intravitreal Injections for DME

Nancy M. Holekamp, MD

OCT-A in Pediatric Patients

Lejla Vajzovic, MD

Back to All Videos

Key Points From the Phase 3 PANORAMA Study

Charles C. Wykoff, MD, PhD, FACS

Posted: 7/20/2018

Keywords:

Diabetic Retinopathy

•

Eylea

•

Intravitreal Injection

•

Regeneron Pharmaceuticals

Please log in to leave a comment.

Comments

Tarik Saddik

6 years ago

I would agree to individualize the treatment . I would be more encouraged to inject pts who have a poor history of HbA1c for last 1-2 yrs , a pt who has fellow eye with high risk PDR , pt with high BP , and pt with advanced diabetic nephropathy

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Key Points From the Phase 3 PANORAMA Study

Up Next

Key Points From the Phase 3 PANORAMA Study

Comments

More From ASRS: 2018 Coverage